Expression and clinical significance of Cripto-1 and mTOR in cervical cancer
10.3760/cma.j.cn431274-20200930-01362
- VernacularTitle:宫颈癌组织中Cripto-1、mTOR的表达及临床意义
- Author:
Xia MENG
1
;
Zhiling YANG
;
Rui XIANG
;
Haifeng LIU
;
Jingyi WANG
Author Information
1. 成都医学院第二附属医院（核工业四一六医院）妇产科 610051
- From:
Journal of Chinese Physician
2020;22(11):1611-1614,1618
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the expression and clinical significance of teratocarcinoma-derived growth factor 1 (Cripto-1) and mammalian target of rapamycin (mTOR)in cervical cancer (CC)cancer tissues.Methods:From January 2012 to May 2017, 152 patients with CC in the 2nd Affiliated Hospital of Chengdu Medical College were selected as CC group, and 40 patients with uterine fibroids as control group. The quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of Cripto-1 and mTOR in 152 cases of CC tissues and 40 cases of normal cervical tissues. The expression difference between the two and their relationship with pathological features and prognosis were statistically analyzed.Results:The relative expression of Cripto-1 and mTOR in CC tissues was significantly higher than that in normal cervical tissues ( P<0.05). There was a significant positive correlation between Cripto-1 and mTOR expression in CC tissues ( r=0.634, P<0.05). The expression of Cripto-1 and mTOR protein in CC tissues were associated with International Federation of Gynecology and Obstetrics (FIGO) stage and tumor grade ( P<0.05), but not with age, pathological type, depth of invasion and lymph node metastasis ( P>0.05). The 3-year overall survival (OS) rate of patients with high Cripto-1 expression was not significantly different from that of patients with low Cripto-1 expression ( P>0.05), while the 3-year OS of high mTOR expression group was significantly lower than that of low mTOR expression group (χ 2=5.808, P=0.016). Conclusions:The expression of Cripto-1 and mTOR is increased in CC tissues.Both of them are related to FIGO stage and tumor grade, which may become a new molecular marker for diagnosis, treatment and evaluation of CC.
